Anti-Human IL13 Therapeutic Antibody (Tralokinumab)

Cat. No.: TAB-218
This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview
Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.

Host Species
Human

Specificity
Tested positive against native human antigen.

Target
IL13

Immunogen
The details of the immunogen for this antibody are not available.

Derivation
Human

Species Reactivity
Human

Type
IgG4 - lambda

Expression Host
CHO

CAS
1044515-88-9

Generic Name
Tralokinumab

MW
143.87 kDa

Purity
>95.0%. Determined by analysis by RP-HPLC & analysis by SDS-PAGE.

Applications
ELISA, FC, IP, FuncS, IF, Neut, ICC

Application Notes
The IL13 antibody has been reported in applications of Inhib, X-ray structure, IHC, RT-
### PCR.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>C_{6374}H_{9822}N_{1698}O_{2014}S_{44}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>1mg</td>
</tr>
<tr>
<td>Storage</td>
<td>At -20°C for one year.</td>
</tr>
<tr>
<td>Related Disease</td>
<td>Asthma, severe</td>
</tr>
</tbody>
</table>

### BACKGROUND

**Introduction**

Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.

**Alternative Names**

Tralokinumab; 1044515-88-9; CAT-354; BAK502G9; IL13; interleukin 13; interleukin-13; allergic rhinitis; ALRH; BHR1; Bronchial hyperresponsiveness 1 (bronchial asthma); IL13; MGC116786; MGC116788; MGC116789; P600; Bronchial hyperresponsiveness-1 (bronchial asthma); IL-13;

**Gene ID**

3596

**UniProt ID**

P35225